These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 26641242)

  • 41. Review article: current management of primary sclerosing cholangitis.
    Cullen SN; Chapman RW
    Aliment Pharmacol Ther; 2005 Apr; 21(8):933-48. PubMed ID: 15813829
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis.
    Stiehl A
    Ital J Gastroenterol; 1996 Apr; 28(3):178-80. PubMed ID: 8789831
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Management of primary sclerosing cholangitis: conventions and controversies.
    Chandok N; Hirschfield GM
    Can J Gastroenterol; 2012 May; 26(5):261-8. PubMed ID: 22590699
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of Primary Sclerosing Cholangitis Including Transplantation.
    Wheless WH; Russo MW
    Clin Liver Dis; 2024 Feb; 28(1):171-182. PubMed ID: 37945158
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Primary sclerosing cholangitis: summary of a workshop.
    LaRusso NF; Shneider BL; Black D; Gores GJ; James SP; Doo E; Hoofnagle JH
    Hepatology; 2006 Sep; 44(3):746-64. PubMed ID: 16941705
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.
    Pardi DS; Loftus EV; Kremers WK; Keach J; Lindor KD
    Gastroenterology; 2003 Apr; 124(4):889-93. PubMed ID: 12671884
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC).
    Mattner J
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834858
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
    Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
    Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives.
    Barba Bernal R; Ferrigno B; Medina Morales E; Castro CM; Goyes D; Trivedi H; Patwardhan VR; Bonder A
    Turk J Gastroenterol; 2023 Feb; 34(2):89-100. PubMed ID: 36843300
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Emerging treatments for primary sclerosing cholangitis.
    Rodriguez EA; Carey EJ; Lindor KD
    Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):451-459. PubMed ID: 28276816
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities.
    Vesterhus M; Karlsen TH
    J Gastroenterol; 2020 Jun; 55(6):588-614. PubMed ID: 32222826
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group.
    van Hoogstraten HJ; Vleggaar FP; Boland GJ; van Steenbergen W; Griffioen P; Hop WC; van Hattum J; van Berge Henegouwen GP; Schalm SW; van Buuren HR
    Am J Gastroenterol; 2000 Aug; 95(8):2015-22. PubMed ID: 10950051
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New therapeutic option with N-acetylcysteine for primary sclerosing cholangitis: two case reports.
    Ozdil B; Cosar A; Akkiz H; Sandikci M; Kece C
    Am J Ther; 2011 May; 18(3):e71-4. PubMed ID: 20019586
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Cholestatic liver diseases].
    Thimme R; Opitz OG; Blum HE; Kreisel W
    Ther Umsch; 2004 Aug; 61(8):521-7. PubMed ID: 15457969
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study.
    Garioud A; Seksik P; Chrétien Y; Corphechot C; Poupon R; Poupon RE; Chazouillères O
    Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):842-7. PubMed ID: 19779305
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Update on primary sclerosing cholangitis.
    Karlsen TH; Schrumpf E; Boberg KM
    Dig Liver Dis; 2010 Jun; 42(6):390-400. PubMed ID: 20172772
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic approaches for hepatobiliary disorders with ursodeoxycholic acid and bile-acid derivatives.
    Serfaty L; Poupon R
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S1. PubMed ID: 23141887
    [No Abstract]   [Full Text] [Related]  

  • 58. URSO not so good for PSC.
    Petruff CA
    Inflamm Bowel Dis; 1998 May; 4(2):172-3. PubMed ID: 9589304
    [No Abstract]   [Full Text] [Related]  

  • 59. Gut microbiome in primary sclerosing cholangitis: A review.
    Little R; Wine E; Kamath BM; Griffiths AM; Ricciuto A
    World J Gastroenterol; 2020 Jun; 26(21):2768-2780. PubMed ID: 32550753
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Treatment of cholestatic liver disease].
    Pleşa A
    Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):733-6. PubMed ID: 14756010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.